Rodney Rietze, iVexSol CEO

Bris­tol My­ers, Charles Riv­er join Se­ries A fund­ing for iVex­Sol

Mass­a­chu­setts-based iVex­Sol has se­cured fund­ing to the tune of $23.8 mil­lion in its lat­est Se­ries A round. The new in­vestors in­clude Bris­tol My­ers Squibb, man­u­fac­tur­er Charles Riv­er Lab­o­ra­to­ries and Asahi Ka­sei Med­ical.

iVex­Sol is a man­u­fac­tur­er of lentivi­ral vec­tors (LVV), used in mak­ing gene ther­a­pies, and this lat­est round of fundrais­ing brings its to­tal Se­ries A to­tal over $39 mil­lion, which will be used to re­cruit more em­ploy­ees and bol­ster its tech­nol­o­gy.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.